Stock Ratings / Health Care / MEDS / financials

HKPD (51) COSM (31) ESYN (41) ZSTK (31) ⌘ Pro Terminal →

DataMeds AI Inc. (MEDS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.03 -7.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

DataMeds AI Inc. (MEDS) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $9.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MEDS)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How MEDS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $23.3M

FY24

Rev $18.1M

FY25

Rev $23.3M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$23.3M	-27.5%	-80%	-$101.3M	-$10.9M	-45%
FY 2024	$18.1M	9.7%	-33.9%	-$6.9M	-$1.2M	-28.3%
FY 2023	$23.3M	8%	-12.3%	-$2.9M	-$349.1K	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MEDS)

✓Walkthrough of MEDS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MEDS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.09%📐 HORIZONTAL RANGE

2026-10-30O $1.94H $2.03L $1.86C $2.03VOL 145.5K

RES: $12.61SUP: $-0.70SMA50: $2.47SMA200: $5.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MEDS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MEDS Butterfly Map → + Track MEDS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +28.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MEDS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MEDS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MEDS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MEDS)

Health Care Rank #948 of 1016 ⚔️ HKPD vs MEDS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MEDS vs. HKPD, COSM, ESYN, ZSTK)

Industry: Other Pharmaceuticals (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DataMeds AI Inc. (MEDS) ranks #948 by composite RQD confidence (30/100, grade E) and #897 by equity capitalization ($9.8M). Within this direct 5-issuer industry benchmark cohort, MEDS leads on earnings valuation at N/A trailing P/E, while MEDS leads on capital efficiency and profitability with -35.0% ROIC and -27.5% gross margin. HKPD currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with MEDS at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MEDS ACTIVE DataMeds AI Inc.	E	30/100	—	-27.5%	-35.0%	-7.73%	$9.8M	Benchmark Subject
HKPD Cellyan Biotechnology Co. Ltd (Class A)	D	51/100	—	—	—	+0.46%	$5.4M	/hkpd-vs-meds →
COSM Cosmos Health Inc.	E	31/100	—	12.1%	-35.0%	+11.45%	$27.9M	/cosm-vs-meds →
ESYN EnerSyn Global Inc.	D-	41/100	—	53.0%	-35.0%	+3.10%	$54.4M	/esyn-vs-meds →
ZSTK ZeroStack Corp.	E	31/100	—	4.6%	-35.0%	-0.34%	$63.9M	/zstk-vs-meds →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002030763

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DataMeds AI Inc. (MEDS) reported GAAP revenue of $23.3M (+28.7% vs. FY2024 revenue of $18.1M ) , GAAP net income of -$101.3M, operating cash flow of -$10.9M, and free cash flow of -$10.9M (-786.1% YoY). On the balance sheet, MEDS closed FY2025 with $30.5M in total assets against $12.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$23.3M	-$101.3M	-$10.9M	-$10.9M	$30.5M	$12.6M
FY2024 (FY)	2024-12-31	$18.1M	-$6.9M	-$1.2M	-$1.2M	$57.3M	$11.5M
FY2023 (FY)	2023-12-31	$0	-$2.9M	-$349.1K	-$349.1K	—	—

3. MEDS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MEDS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, DataMeds AI Inc. (NASDAQ: MEDS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.03 (-7.73% 1D, market cap $9.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MEDS ranks #948 in composite RQD confidence.

How does MEDS compare to HKPD and COSM in the Health Care sector?

Within the Health Care sector (Other Pharmaceuticals), MEDS carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of -27.5%, and ROIC of -35.0%. By comparison, HKPD (Cellyan Biotechnology Co. Ltd (Class A)) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $5.4M) and COSM (Cosmos Health Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $27.9M). Among the 5-stock peer group, MEDS leads on earnings multiple (N/A) while MEDS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MEDS?

Per MEDS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002030763), DataMeds AI Inc. generated $23.3M in revenue (+28.7% YoY), -$101.3M in net income, and -$10.9M in free cash flow against $30.5M in total assets and $12.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MEDS trading relative to its 50-day, 200-day, and 52-week technical levels?

MEDS last traded at $2.03 (-7.73% on volume of 227,883 shares), positioning the stock -17.81% below its 50-day simple moving average ($2.47) and -65.36% below its 200-day simple moving average ($5.86). Across its 52-week range of $0.82 to $35.70, MEDS sits at the 3.5% percentile with a 14-day RSI of 38.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.78 to $2.28).